文献速递外周动脉疾病

ACEI/ARB与膝下动脉干预后重症肢体缺血患者保肢改善相关

Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers (ACEI/ARB) are Associated with Improved Limb Salvage after Infrapopliteal Interventions for Critical Limb Ischemia.
PubMed 文献 · Ann Vasc Surg · 2019-10-15

该回顾性研究纳入755条肢体(611例患者),比较ACEI/ARB使用与否对重症肢体缺血血运重建后通畅率与保肢的影响。膝下动脉干预中ACEI/ARB组60个月保肢率显著更高(75% vs 61%,P=0.005),股腘动脉干预则无差异,且ACEI/ARB与通畅率无关。

要点

  • ACEI/ARB对膝下及股腘动脉干预的初期和二期通畅率均无显著影响。
  • ACEI/ARB与免于MACE及总生存无显著差异,但呈现改善趋势。

核心结论

  • ACEI/ARB与膝下动脉干预的CLI患者保肢改善相关,但与股腘动脉干预无关。
  • ACEI/ARB对通畅率无影响,与免于MACE和生存改善呈趋势但无统计学差异。

研究设计与样本

  • 回顾性识别2001年6月至2014年12月因CLI(Rutherford 4-6)行腹股沟下血运重建的患者。
  • 共纳入611例患者的755条肢体,其中ACEI/ARB组311条,无ACEI/ARB组300条。
  • 采用Kaplan-Meier计算通畅率、保肢率、MACE和生存率,Cox回归进行多因素分析。

主要发现

  • ACEI/ARB组高血压(86% vs 70%,P<0.001)、糖尿病(68% vs 55%,P=0.001)和他汀使用(61% vs 45%,P<0.001)比例显著更高。
  • 膝下动脉干预60个月保肢率ACEI/ARB组75% vs 无ACEI/ARB组61%(P=0.005)。
  • 膝下动脉干预60个月初期通畅率45% vs 46%(P=0.66),二期通畅率62% vs 75%(P=0.96)。
  • 股腘动脉干预60个月初期通畅率54% vs 55%(P=0.47),二期通畅率76% vs 75%(P=0.83),保肢率84% vs 87%(P=0.36)。

临床怎么用

  • 对于接受膝下动脉干预的CLI患者,使用ACEI/ARB可能改善保肢结局。
  • ACEI/ARB不影响通畅率,不应以改善通畅率为目的处方。

局限性

  • 回顾性设计,存在选择偏倚可能。
  • ACEI/ARB组高血压、糖尿病和他汀使用比例更高,混杂因素可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Angiotensin-converting enzyme Inhibitors and Angiotensin II Receptor Blockers (ACEI/ARB) reduce the risk of cardiovascular events and mortality in patients with peripheral arterial disease (PAD). However, their effect on limb-specific outcomes is unclear. The objective of this study is to assess the effect of ACEI/ARB on patency and limb salvage in patients undergoing interventions for critical limb ischemia (CLI). METHODS: Patients undergoing infrainguinal revascularization for CLI (Rutherford 4-6) between 06/2001 and 12/2014 were retrospectively identified. Primary Patency (PP), Secondary Patency (SP), Limb Salvage (LS), major adverse cardiac events (MACE), and survival rates were calculated using Kaplan-Meier. Multivariate analysis was performed using Cox regression. RESULTS: A total of 755 limbs in 611 patients (311 ACEI/ARB, 300 No ACEI/ARB) were identified. Hypertension (86% vs. 70%, P < 0.001), diabetes (68% vs. 55%, P = 0.001) and statin use (61% vs. 45%, P < 0.001) were significantly greater in the ACEI/ARB group. Interventions were performed mostly for tissue loss (83% ACEI/ARB vs. 84% No ACEI/ARB, P = 0.73). Comparing ACEI/ARB versus No ACEI/ARB, in femoropopliteal interventions, 60-month PP (54% vs. 55%, P = 0.47), SP (76% vs. 75%, P = 0.83) and LS (84% vs. 87%, P = 0.36) were not significantly different. In infrapopliteal interventions, 60-month PP (45% vs. 46%, P = 0.66) and SP (62% vs. 75%, P = 0.96) were not significantly different. LS was significantly greater in ACEI/ARB (75%), as compared to No ACEI/ARB (61%) (P = 0.005). Cox regression identified diabetes (HR 2.4 (1.4-4.1), P = 0.002), ESRD (HR 3.5 (2.1-5.7), P < 0.001), hypertension (HR 0.4 (0.2-0.6), P < 0.001), and ACEI/ARB (HR 0.6 (0.4-0.9), P = 0.03), as factors independently associated with LS after infrapopliteal interventions. Freedom from MACE (ACEI/ARB 37% vs. 32%, P = 0.82) and overall survival (ACEI/ARB 42% vs. 35% No ACEI/ARB, P = 0.84) were not significantly different. CONCLUSIONS: ACEI/ARB is associated with improved limb salvage in CLI patients undergoing infrapopliteal interventions, but not after femoropopliteal interventions. ACEI/ARB had no impact on patency rates. They were also associated with a trend toward improved survival and freedom from MACE. Our findings suggest that the use of ACEI/ARB may improve outcomes in the high-risk CLI patient population.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Khan SZ, Montross B, Rivero M, et al. Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers (ACEI/ARB) are Associated with Improved Limb Salvage after Infrapopliteal Interventions for Critical Limb Ischemia. Ann Vasc Surg. 2019. PMID: 31626938. doi:10.1016/j.avsg.2019.08.093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。